Brenus Pharma and Champions Oncology advance patient-aligned 3D tumor platform to bridge translational gaps in “cold” solid tumors.
At SITC 2026 (Phoenix, November 4–8), Brenus Pharma and Champions Oncology presented their collaboration evaluating STC-1010, an active immunotherapy, in patient-derived 3D tumor cultures, an innovative approach to study tumor–immune dynamics and biomarkers of response in “cold” solid tumors.